Theravance (THRX +3.2%) and GlaxoSmithKline (GSK +0.1%) have submitted a regulatory application to the E.U. for Anoro, an investigational combination medicine for patients with chronic obstructive pulmonary disease. The companies submitted a regulatory application in the U.S. for the drug last December.
Theravance (THRX +3.2%) and GlaxoSmithKline (GSK +0.1%) have submitted a regulatory application...
From other sites
at CNBC.com (Jun 11, 2014)
at CNBC.com (Dec 6, 2013)
at CNBC.com (Sep 10, 2013)
at CNBC.com (Jun 24, 2013)
at CNBC.com (Apr 15, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs